
    
      This is an open-label (all people know the identity of the intervention), multi-center (study
      conducted at multiple sites), uncontrolled (all the patients receiving darunavir) clinical
      and observational study (study in which the investigators/physicians observe the patients and
      measure their outcomes) to evaluate the safety and effectiveness of darunavir for the
      treatment human immunodeficiency virus-type 1 (HIV-1) infection among adult Filipino
      patients. The study will enroll 10 percentage of patient who would use the product, as a
      requirement of the Philippine Food and Drug Administration (FDA). Patients will be monitored
      from baseline and every 4 weeks thereafter for a period of 24 weeks. Safety evaluations for
      adverse events, clinical laboratory tests, physical examination, concomitant medications, and
      co-morbid conditions will be monitored throughout the study. The duration of treatment will
      be for 24 weeks and the total study will be conducted for 3 years.
    
  